The estimated Net Worth of James Schaub is at least 1.95 百万$ dollars as of 16 December 2021. Mr. Schaub owns over 93,800 units of Osmotica Pharmaceuticals Plc stock worth over 450,549$ and over the last 6 years he sold OSMT stock worth over 0$. In addition, he makes 1,496,500$ as Chief Operating Officer、 Executive Vice President at Osmotica Pharmaceuticals Plc.
James has made over 1 trades of the Osmotica Pharmaceuticals Plc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 93,800 units of OSMT stock worth 100,366$ on 16 December 2021.
The largest trade he's ever made was buying 93,800 units of Osmotica Pharmaceuticals Plc stock on 16 December 2021 worth over 100,366$. On average, James trades about 13,400 units every 0 days since 2019. As of 16 December 2021 he still owns at least 405,900 units of Osmotica Pharmaceuticals Plc stock.
You can see the complete history of Mr. Schaub stock trades at the bottom of the page.
James Schaub serves as Chief Operating Officer, Executive Vice President of the Company. Prior to that he served as Chief Operating Officer, Trigen Laboratories beginning in December 2013. Mr. Schaub previously served as Vice President, M&A of Fougera Pharmaceuticals, Inc. from August 2011 to September 2012. Prior to that, Mr. Schaub spent five years with King Pharmaceuticals, Inc., where he held several commercial roles of increasing responsibility. He joined our company in December 2013. Mr. Schaub holds a B.A. in Economics from Middlebury College and an M.B.A. from Rutgers Business School.
As the Chief Operating Officer、 Executive Vice President of Osmotica Pharmaceuticals Plc, the total compensation of James Schaub at Osmotica Pharmaceuticals Plc is 1,496,500$. There are 3 executives at Osmotica Pharmaceuticals Plc getting paid more, with Brian Markison having the highest compensation of 4,338,620$.
James Schaub is 38, he's been the Chief Operating Officer、 Executive Vice President of Osmotica Pharmaceuticals Plc since 2016. There are 15 older and 1 younger executives at Osmotica Pharmaceuticals Plc. The oldest executive at Osmotica Pharmaceuticals Plc is Fred Weiss, 78, who is the Independent Director.
James's mailing address filed with the SEC is C/O OSMOTICA PHARMACEUTICALS PLC, 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.
Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over 0$ worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth 31,350,366$ . The most active insiders traders include David F Burgstahler、Sriram Venkataraman、Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of 1,173,603$. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth 100,366$.
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include: